TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19125977

Group type: EXPERIMENTAL
Intervention: Alpha System
Number of subjects: 45

Group type: COMPARATOR
Intervention: ProTaper Universal
Number of subjects: 45

Group type: COMPARATOR
Intervention: Stainless Steel Hand Instruments
Number of subjects: 45
Study: 18042770

Group type: EXPERIMENTAL
Intervention: Ministernotomy (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Full sternotomy (group 1)
Number of subjects: 60
Study: 15252700

Group type: EXPERIMENTAL
Intervention: Varying the direction of motion (from 0 degrees to 315 degrees in steps of 45 degrees)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Varying the size of the targets (W: 2.5, 1.25, and 0.625 cm)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nature of the mapping (linear or non-linear) between effector space and task space
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Biomechanical constraints at the level of the effector
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Informational constraints at the level of the task
Number of subjects: 9
Study: 11679925

Group type: EXPERIMENTAL
Intervention: Low-, medium-, or high-dose recombinant gp120 vaccine with MF59 adjuvant
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Accelerated vaccine schedule (birth and ages 2, 8, and 20 weeks) with defined optimal dose
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (MF59 alone)
Number of subjects: 61
Study: 10209587

Group type: EXPERIMENTAL
Intervention: Soft Cast (semi-rigid cast)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Scotchcast Plus (rigid cast)
Number of subjects: 57
Study: 8135449

Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g every 4 hours
Number of subjects: 244

Group type: COMPARATOR
Intervention: Antacid (aluminum hydroxide and magnesium hydroxide), 20 mL every 2 hours
Number of subjects: 244

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg as a continuous intravenous infusion
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 244
Study: 2644391

Group type: EXPERIMENTAL
Intervention: 2-g single dose of metronidazole for male partners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seven-day course of 500 mg metronidazole twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole
Number of subjects: 0
Study: 1261583

Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Practolol (0.1 mg/kg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of practolol and verapamil (0.1 mg/kg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of practolol and verapamil (practolol preceding verapamil)
Number of subjects: 10
Study: 29761537

Group type: EXPERIMENTAL
Intervention: Loaded isometric contraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal posture
Number of subjects: 40
Study: 27899754

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation combined with constraint-induced movement therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation combined with constraint-induced movement therapy
Number of subjects: 44
Study: 25381458

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: COMPARATOR
Intervention: Other therapies
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 175
Study: 23642843

Group type: EXPERIMENTAL
Intervention: Direct-lateral exposure (DL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Antero-lateral exposure (AL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Posterior exposure (P)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 72
Study: 21501814

Group type: EXPERIMENTAL
Intervention: Comprehensive support intervention (school fees, uniforms, community visitor monitoring)
Number of subjects: 105
Study: 20415933

Group type: EXPERIMENTAL
Intervention: Fluconazole mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clotrimazole mouthpaint
Number of subjects: 0
Study: 17724283

Group type: EXPERIMENTAL
Intervention: ZNS 5 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ZNS 10 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15134386

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CHS) 800 mg orally plus naproxen 500 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naproxen 500 mg only
Number of subjects: 24
Study: 11822472

Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg/day for 5 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (5 days)
Number of subjects: 66
Study: 9680769

Group type: EXPERIMENTAL
Intervention: 5% salicylic acid and 10% urea ointment (Kerasal)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 12% ammonium lactate lotion (Lac‐Hydrin)
Number of subjects: 70
Study: 8043891

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2545366

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ivermectin 150 mcg/kg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ivermectin 200 mcg/kg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 30601345

Group type: EXPERIMENTAL
Intervention: Text message appointment reminder
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard scheduling with no reminder
Number of subjects: 123
Study: 29629778

Group type: EXPERIMENTAL
Intervention: Immediate coaching
Number of subjects: 89

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 89
Study: 28371872

Group type: EXPERIMENTAL
Intervention: Rainy season
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Reference ranges
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Neutrophil levels
Number of subjects: 501
Study: 26253152

Group type: EXPERIMENTAL
Intervention: Seasonal and multiannual cash transfers via mobile phones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no cash transfers)
Number of subjects: 0
Study: 23903014

Group type: EXPERIMENTAL
Intervention: Donor stem cell infusion (DSCI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no DSCI)
Number of subjects: 9
Study: 21913140

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (3 ml · kg (‐1) body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 10
Study: 18312401

Group type: EXPERIMENTAL
Intervention: GW406381 (70 mg)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: naproxen sodium (825 mg)
Number of subjects: 337

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 337
Study: 17060219

Group type: EXPERIMENTAL
Intervention: Two commonly used treatments for liquid aspiration
Number of subjects: 0
Study: 12928123

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 176
Study: 10666521

Group type: EXPERIMENTAL
Intervention: Epidural morphine preemptively before surgery and maintained until skin closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control preemptively before surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural morphine post-surgery via PCA pump
Number of subjects: 0
Study: 9087009

Group type: EXPERIMENTAL
Intervention: Occlusive dressing (OpSite Flexigrid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intact skin underneath the dressing
Number of subjects: 8
Study: 7828490

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastroenterostomy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Billroth type-II gastroenterostomy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Surgery (both procedures)
Number of subjects: 14
Study: 2462651

Group type: EXPERIMENTAL
Intervention: Estracyt (E) + Peplomycin (P) + Doxorubicin (Do) in Group 1
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: E + P in Group 2
Number of subjects: 2

Group type: COMPARATOR
Intervention: Various treatment subgroups
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: PAP-related response in Group 2
Number of subjects: 2
Study: 31869494

Group type: EXPERIMENTAL
Intervention: Ventilation tube (VT) surgery
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: VT surgery between 5 weeks and 6 months
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: VT surgery between 6 and 12 months
Number of subjects: 327
Study: 29038285

Group type: EXPERIMENTAL
Intervention: Caloric restriction and aerobic exercise
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Caloric restriction alone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Aerobic exercise alone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Combined intervention (caloric restriction and aerobic exercise)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 111
Study: 28843009

Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (DBS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Circular deep brain stimulation (DBS)
Number of subjects: 10
Study: 25377507

Group type: EXPERIMENTAL
Intervention: ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin)
Number of subjects: 140

Group type: COMPARATOR
Intervention: pemetrexed and carboplatin (or cisplatin)
Number of subjects: 140
Study: 21812822

Group type: EXPERIMENTAL
Intervention: Intermittent Agility Exercise (IAE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 21600163

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both Remifentanil and Sufentanil
Number of subjects: 40
Study: 18496020

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) course, 8 weeks duration, 15 participants
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated comparison group, 7 participants
Number of subjects: 22
Study: 17142411

Group type: EXPERIMENTAL
Intervention: Circular external fixation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 82
Study: 14520769

Group type: EXPERIMENTAL
Intervention: Diclofenac-K (12.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10716135

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg once daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: enalapril 20 mg once daily
Number of subjects: 142
Study: 9178399

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms bid)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms bid) and Placebo
Number of subjects: 208
Study: 1283198

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 8 ml bupivacaine 0.5% + 5 ml lignocaine 2%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 20
Study: 3087550

Group type: EXPERIMENTAL
Intervention: Subcutaneous estradiol implants combined with cyclical oral norethisterone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 29802443

Group type: EXPERIMENTAL
Intervention: Low-dose X-82 (200 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-dose X-82 (400 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: X-82 alone (cycle 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: X-82 plus docetaxel (cycle 2)
Number of subjects: 14
Study: 26385456

Group type: EXPERIMENTAL
Intervention: Prenatal yoga intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perinatal-focused health education (Control)
Number of subjects: 0
Study: 24524389

Group type: EXPERIMENTAL
Intervention: Probiotics (Group A)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (Group B)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Neither probiotics nor oral antibiotics (Group C)
Number of subjects: 310
Study: 22875686

Group type: EXPERIMENTAL
Intervention: Participatory research elective class
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 401
Study: 20725123

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (IHE)
Number of subjects: 9
Study: 18848381

Group type: COMPARATOR
Intervention: Fluoxetine (20mg daily for 90 days)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (10 sessions)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study: 15679557

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 1034
Study: 14501863

Group type: EXPERIMENTAL
Intervention: Right liver graft without MHV trunk or MHV reconstruction (n=17)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Right liver graft without MHV trunk, but with MHV reconstruction (n=27)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Extended right liver graft (n=12)
Number of subjects: 56
Study: 10596917

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) 800 mg/m2 every 21 days, IL-2 9 MIU subcutaneously days 1-5 and 8-12, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 days 1-3, DTIC 250 mg/m2 days 1-3, vindesine 2.5 mg/m2 day 1 every 28 days, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cisplatin, DTIC, vindesine (CVD) plus IL-2 6 MIU days 1-5 and 8-12 every 28 days, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: All arms (A, B, C)
Number of subjects: 92
Study: 8992424

Group type: EXPERIMENTAL
Intervention: Etoposide (100 mg/m2/1h) administered immediately before and at the end (24th h) of methotrexate treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Etoposide (100 mg/m2/1h) administered at 24 h and at 48 h after starting methotrexate infusion
Number of subjects: 2
Study: 1714948

Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Radiotherapy after orchiectomy
Number of subjects: 150
Study: 7105823

Group type: EXPERIMENTAL
Intervention: Film-coated indoramin (50 mg tablets)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Uncoated indoramin (50 mg tablets)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Film-coated indoramin after a standard meal
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Film-coated indoramin (2 tablets)
Number of subjects: 7
Study: 31491757

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia, followed by epidural analgesia for 48 hours after surgery
Number of subjects: 48

Group type: COMPARATOR
Intervention: General anesthesia, followed by traditional opioid pain management after surgery
Number of subjects: 48
Study: 26082384

Group type: EXPERIMENTAL
Intervention: Laminectomy followed by fusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Laminectomy without fusion
Number of subjects: 18
Study: 26265232

Group type: EXPERIMENTAL
Intervention: PH‐797804 30 mg (oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐03715455 20 mg (inhaled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 μg (inhaled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PH‐797804
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐03715455
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PH‐797804 and PF‐03715455
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0
Study: 24603110

Group type: EXPERIMENTAL
Intervention: Dilation by one-stage Amplatz (group II)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Dilation by serial metallic dilators (group I)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 22081122

Group type: COMPARATOR
Intervention: Traditional logopedic dysphagia treatment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Traditional logopedic dysphagia treatment combined with NMES at sensor or motor level stimulation
Number of subjects: 88
Study: 20815879

Group type: EXPERIMENTAL
Intervention: A-L dispersible tablet (cherry flavour)
Number of subjects: 48

Group type: COMPARATOR
Intervention: A-L dispersible tablet (80 mg artemether + 480 mg lumefantrine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: A-L dispersible tablet
Number of subjects: 48
Study: 17132823

Group type: EXPERIMENTAL
Intervention: GH (2 mg daily)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GH (2 mg daily) + Acipimox (250 mg x 3 daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 9
Study: 15876939

Group type: EXPERIMENTAL
Intervention: PnCV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12059913

Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 80

Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 80

Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 80
Study: 9536401

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract/carboxymethyl-beta-1,3-glucan formulation applied 2X a day for 2 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7664371

Group type: EXPERIMENTAL
Intervention: One channel sputum sucking for 15 sec (Experimental Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oxygen supplied double channel sucking for 15 sec (Experimental Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Channel sputum sucker under mechanical respiratory support (Contrast Group)
Number of subjects: 90
Study: 2545773

Group type: EXPERIMENTAL
Intervention: Oral dextroamphetamine 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prior treatment with pimozide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Thymoxamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 24
Study: 352197

Group type: EXPERIMENTAL
Intervention: Cloprednol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30747030

Group type: EXPERIMENTAL
Intervention: Nostalgia condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ordinary condition (Control)
Number of subjects: 60
Study: 27918172

Group type: EXPERIMENTAL
Intervention: Bridges to High School intervention
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 516
Study: 25724103

Group type: EXPERIMENTAL
Intervention: Versajet™ hydrosurgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional debridement
Number of subjects: 61
Study: 24342196

Group type: EXPERIMENTAL
Intervention: Iron protein succinylate (IPS) oral solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Polysaccharide iron complex (PIC)
Number of subjects: 60
Study: 21679323

Group type: EXPERIMENTAL
Intervention: Guided skiing for 12 weeks (IG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study: 19494809

Group type: EXPERIMENTAL
Intervention: Tacrolimus-treated patients who were UGT1A9 -275T>A and/or -2152C>T carriers
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: UGT1A9*3 carriers treated with tacrolimus
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: UGT1A9*3 carriers treated with cyclosporine
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Cyclosporine-treated UGT1A8*2/*2 (518GG) patients
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Fixed-dose MMF-treated patients receiving tacrolimus with UGT1A9 -275T>A and/or -2152C>T polymorphism
Number of subjects: 338
Study: 16461866

Group type: EXPERIMENTAL
Intervention: CM and 300 mg/d of bupropion hydrochloride (CMB)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CM and placebo (CMP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: voucher control and bupropion (VCB)
Number of subjects: 106

Group type: COMPARATOR
Intervention: voucher control and placebo (VCP)
Number of subjects: 106
Study: 15104569

Group type: COMPARATOR
Intervention: 75 IU rLH supplementation (group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 150 IU rLH supplementation (group B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (C) with rFSH monotherapy
Number of subjects: 46
Study: 15354458

Group type: EXPERIMENTAL
Intervention: 0.42% fluoride gel (8 applications at 3-month intervals)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no fluoride gel)
Number of subjects: 213
Study: 9003817

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 208
Study: 8515294

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ciprofloxacin plus amoxicillin
Number of subjects: 53
Study: 3556337

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg orally
Number of subjects: 2
Study: 28502270

Group type: EXPERIMENTAL
Intervention: Insecure attachment (fearful-avoidant, dismissing, preoccupied)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Fearful-avoidant attachment style
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Preoccupied attachment style
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Insecure attachment overall
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Dismissing attachment style
Number of subjects: 162
Study: 26796355

Group type: EXPERIMENTAL
Intervention: Blood pressure control >_75% of visits
Number of subjects: 6287

Group type: COMPARATOR
Intervention: Blood pressure control < 25% of visits
Number of subjects: 6287
Study: 24599922

Group type: EXPERIMENTAL
Intervention: Biologics plus MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 0